layout

wide boxed

direction

ltr rtl

style

light dark

skins

default alimbalmarina somnambula juicy spoonflower goats nutricap keratin vit courtly attire mondrian sage walking by

bg pattern

1 2 3 4 5 6 7 8

bg image

1 2 3 4 5 6 7 8

Gano Ultra

GanoUltra™ – Najjača cetiri soja Ganoderme Lucidum  u svetu (Crvena Reishi, Crna Reishi, Ljubicasta Reishi, Bela Reishi).

"GanoUltra™  Super Potent Four Color Reishi Capsules- most potent Ganoderma product available anywhere in the world today".


Tokom istorije tradicionalna kineska medicina (takođe poznata i kao TKM) otkrila je da su Reishi pečurke različitih boja korisne za različite svrhe. Iako je crvena Reishi gljiva daleko najčešća vrsta Ganoderma-e, postoje i ređe i skuplje vrste Reishija koje lekari (TKM) već vekovima veoma visoko cene. Većina tipova Reishija pripada istoj vrsti - Ganoderma lucidum – ali pod različitim uslovima uzgoja Reishi proizvodi širok spektar različitih medicinski aktivnih jedinjenja. Ti različiti uslovi uzgoja uzrokuju promenu boje ploda od crvene do nijansi ljubičaste, odnosno od crvene do toliko tamne da izgleda poput crne.  To su najpotentnije vrste (i najređe!) koje su se koristile u TKM tokom vekova postojanja ovog starog načina lečenja. Pored uobičajenog crvenog oblika, sojevi crne i ljubičaste Ganoderma-e doprinose neverovatnoj širini njenih lekovitih dejstava na organizam. Postoji još jedna Ganoderma koja je još ređa i skuplja, a poznata je kao bela Reishi.  Ova super retka i visoko vredna Reishi pečurka zapravo pripada veoma bliskoj vrsti poznatoj kao Ganoderma applanatum. Tek u poslednjih par godina pojavila se tehnologija (i to samo u Americi) koja nam omogućava uzgoj ovog izuzetno retkog belog oblika Reishija.Aloha Medicinals je jedini uzgajivač ove retke medicinske pečurke danas. S jednakim koncentracijama ova četiri tipa Ganoderma-e, crvene, crne, ljubičaste i bele Reishi pečurke, GanoUltra™ predstavlja napredak u proizvodima TKM na kojima se radi već stotinama godina. GanoUltra™ je proizvod na bazi gljiva punog spektra, sa svim prirodnim antibakterijskim, antivirusnim svojstvima, regulisanjem imuniteta, krvnog pritiska i svim ostalim dragocenim zdravstvenim svojstvima po kojima je Ganoderma poznata kroz svoju dugu istoriju. Nikada do sada nije stvoren ovako potentan-ili ovako dragocen- proizvod na bazi Reishija, a sada nam je na raspolaganju!

Aloha Medicinals je zahvaljujući razvoju biotehnologije uspela da razvije kombinaciju 4 najbolja, 100% USDA sertifikovana organska soja Reishi gljive poznate kao Crvena Reishi "Pure Red Reishi", kojoj je Američka vlada dala status "GanoUltra" proglasivši je najkvalitetnijom Reishi danas u svetu.

Osnovni biološki aktivni sastojci su prirodni polisaharidi-Beta glukani, visoka koncentracija organskog Germanijuma i triterpeni.

Ganodermna kiselina zbog svog izrazitog antivirusnog i antibakterijskog dejstva koristi se kod rizika od infekcija, raznih crevnih oboljenja, hepatitisa i alergija. Polisaharidi ove gljive imaju jak antikancerogeni efekat i u svetu se koriste kao zvanično sredstvo u borbi protiv tumora, pokrećući imunobiološke reakcije kojima organizam menja svoje funkcionisanje kako bi ozdravio.

GanoUltra:

Svaka kapsula GanoUltre  sadrzi 500 mg USDA sertifikovanog organskog cistog koncentrata cetiri najpoznatija roda Reishia (Crveni Reishi, Crni Reishi, Ljubicasti Reishi, Beli Reishi).

Doziranje i nacin upotrebe

Preporučuje se 3 kapsule dnevno. Bilo bi poželjno uzimati sa Vit C u koncentraciji od 2-3 grama jer askorbinska kiselina razbija velike molekule Heteropolysaccharida u manje i samim tim omogucava da se veže za što veći broj imunoloških ćelija organizma. U jednoj bočici ima 90 kapsula.

Aloha Medicinals Inc. je najveći proizvođač imunomodulatora na bazi retkih medicinskih gljiva u svetu. Preparat je registrovan u većini zemalja sveta. 100% proizvedeno u Americi. 100% organiski proizvod. Dijetetski proizvod, apsolutno neškodljiv i nakon dugog uzimanja. Kvalitet aktivne supstance kontroliše vodeća nezavisna laboratorija www.integratedbiomolecule.com

Nijedan preparat se ne može smatrati lekom već dijeteskim suplementima!

Aloha Medicinals Imune Assist Certificates

Aloha Medicinals Imune Assist Certificates

Aloha Medicinals Imune Assist Certificates

Aloha Medicinals Imune Assist Certificates

Aloha Medicinals Imune Assist Certificates

Aloha Medicinals Imune Assist Certificates

Aloha Medicinals Inc. je najveći proizvođač imunomodulatora na bazi retkih medicinskih gljiva u svetu. Preparat je registrovan u većini zemalja sveta. 100% proizvedeno u Americi. 100% organiski proizvod. Dijetetski proizvod, apsolutno neškodljiv i nakon dugog uzimanja. Kvalitet aktivne supstance kontroliše vodeća nezavisna laboratorija www.integratedbiomolecule.com

Nijedan preparat se ne može smatrati lekom već dijeteskim suplementima!

Ovaj tekst i sajt su edukativnog karaktera, namenjeni za opšte obrazovanje i u informativne svrhe, nisu zamena za profesionalni medicinski savet, ispitivanje, dijagnozu ili lečenje.

 

Naučno Ime: Ganoderma Lucidum (hrastova sjajnica)



Japanski naziv: Reishi ili Mannetake (10000-godišnja pečurka/pečurka besmrtnosti)

Kineski naziv: Ling Zhi (duhovna pečurka-pečurka duhovne potencije)

 

 

 

 

 

 

Najpoznatija od svih medicinskih pečurki s godišnjom prodajom od preko 2 milijarde dolara, G. lucidum ima široki spektar zdravstvenih pogodnosti koje duguje visokom sadržaju polisaharida (Stamets izveštava da karpofor sadrži 41% beta- glukana) i jedinjenjima triterpenoida. Identifikovano je preko 130 vrsta koje pripadaju dvema familijama; funkcije ganoderične i luciderične kiseline obuhvataju:

  • Sprečavanje oslobađanja histamina
  • Zaštitu jetre
  • Sprečavanje hipertenzije (AKE inhibitori)
  • Sprečavanje sinteze holesterola
  • Sprečavanje upale
  • Izazivanje apoptoze
  • Sprečavanje virusne indukcije
  • Antioksidantska svojstva
  • Antitumorna svojstva
  • Smirivanje CNS
  • Antimikrobna svojstva
  • Imunomodulatorna svojstva

Nedavno se javilo interesovanje za spore bogate lipidima za koje su in vitro istraživanja pokazala da su antikancerogeni agensi koji sprečavaju pojavu tumora. Međutim, nedavna uporedna istraživanja imunomodulatornih i antitumorskih aktivnosti spora s pocepanim spoljnim omotačem i ekstrakta kompletnog karpofora pokazalo je da spore s pocepanim spoljašnjim omotačem nisu efikasnije u poređenju s ostalim gljivama.

G. lucidum pokazuje izuzetno visoka inhibitorna svojstva monofenol monooksigenaze s najvećom aktivnošću u vodenom ekstraktu. Zbog toga se koristi u mnogim komercijalnim proizvodima za izbeljivanje kože, i ima mnogo medicinskih implikacija, posebno u vezi s Parkinsonovom bolešću.

RAK - G. lucidum ima dugu istoriju tradicionalnog korišćenja u lečenju raka i zaslužna je za mnoge slučajeve spontanog povlačenja.

Pored imunomodulatornog dejstva zbog visokog sadržaja polisaharida, njeni triterpeni pokazuju značajnu citotoksičnu aktivnost protiv različitih ćelijskih linija raka, kao i inhibitorno dejstvo u slučaju Epštajn-Barovog virusa koji se vezuje za pojavu nekih vrsta raka. Pored toga, triterpeni iz G. lucidum pokazuju inhibiciju nuklearnih transkripcionih faktora, NF-kapa B (NF-kB), koji je previše izražen u različitim ćelijskim linijama raka, a takođe i u signalnom putu aktivacionog proeina.

Inhibicija NF-kB posebno je važna za aktivnost G. lucidum u slučajevima raka dojke i raka prostate, jer se smatra da igra najbitniju ulogu u nezavisnom porastu hormona i širenju ovih vrsta raka.

Studije koje proučavaju ekstrakte polisaharida G. lucidum potvrdile su njenu sposobnost poboljšanja imuniteta pacijenata obolelih od raka i to povećanjem nivoa aktivnosti NK ćelija (ćelija ubica) i Th1 citokina, i smanjenjem nivoa Th2 citokina kod pacijenata s rakom pluća u uznapredovalom stadijumu.

ALERGIJE - Pored imunomodulatornih, G. lucidum pokazuje i jaka antiinflamatorna svojstva tako što suzbija faktor nekroze tumora-alfa (TNF-alfa), interleukin-6 (IL-6), azotni oksid (NO) koji omogućava upalu, i prostaglandin E(2), što je olakšano inhibicijom NF-kB i signalnog puta aktivacionog proteina. Ova kombinacija imunomodulatorne i antiinflamatorne aktivnosti povećava njenu efikasnost u lečenju alergija i drugih upalnih oboljenja.

G. lucidum je komponenta FAHF-2, kineske biljne formule za koju se zna da potpuno blokira anafilaktičke reakcije na alergiju na kikiriki kod miševa.

OBOLJENJA JETRE - Već dugo je karpofor G. lucidum popularni tradicionalni lek za oboljenja jetre i dokazao je da poseduje hepatoprotektivna svojstva. Izgleda da G. lucidum duguje deo ovih svojstava sposobnostima triterpena da blokiraju beta receptor faktora rasta krvnih pločica (PDGFbetaR), koji time sprečava aktivaciju i proliferaciju zvezdastih ćelija jetre, ključnog momenta fibroze jetre.

G. lucidum se takođe tradicionalno koristi u lečenju hepatitisa, i u kliničkom istraživanju 355 slučaja lečenja hepatitisa B Wulingdan pilulom koja za glavni sastojak ima G. lucidum, pokazano je da je 92,4% pacijenata pozitivno reagovalo na lečenje. Izgleda da su triterpeni još jednom ključni sastojci u toj vrsti borbe.

HIPERTENZIJA - G. lucidum ima široki uticaj na kardiovaskularno zdravlje. Polisaharidi i triterpeni iz G. lucidum pokazali su hipolipidemijska, hipotenzivna i antitrombotička svojstva, dok je preparat s polisaharidima (Ganopoly) doveo do poboljšanja EKG-a, smanjenja bolova u grudima, palpitacija i kraćeg daha u duplo-slepom nasumičnom višecentarskom istraživanju. Neka jedinjenja triterpenida iz G. lucidum već su pokazala blaga inhibitorna svojstva angiotenzin konvertujućeg enzima.

NESANICA/ANKSIOZNOST - Tradicionalno ime G. lucidum, „duhovna pečurka“, ukazuje na sedativno dejstvo njenih triterpenoidskih sastojaka, i mnogi travari cene njeno dejstvo kod nesanice. Kristofer Hobs preporučuje G. lucidum u slučajevima nesanice, dok je Mizuno preporučuje za „mentalnu stabilizaciju“.

REUMATOIDNI ARTRITIS - Kombinacija imunomodulatornih i antiinflamatornih svojstava G. lucidum sugeriše potencijalnu primenu u lečenju autoimunih stanja poput reumatoidnog artritisa. Dokazano je da deo proteoglikana iz G. lucidum sprečava proizvodnju sinovijalnih fibroblasta reumatoidnog artritisa in vitro, delom i putem inhibicije transkripcijskih puteva NF-kB.

USPORAVA STARENJE - Dokazano je da ekstrakt G. lucidum, za koju se dugo smatralo da poboljšava dugovečnost, inhibira beta-amiloidnu sinaptičku toksičnost i ima potencijalno dejstvo protiv Alchajmerove bolesti. Pored toga, široki spektar kardiovaskularnih, neuroloških i imunoliških efekata G. lucidum uz pozitivne efekte kontrole šećera i holesterola u krvi čine G. lucidum odličnim opštim zdravstvenim suplementom.

KRATAK KLINIČKI PREGLED

Osnovna primena u terapiji: alergije, unapređenje funkcija jetre, rak (posebno dojke i prostate), hipertenzija, nesanica/anksioznost.

Pored Cordyceps Sinesis, G. lucidum ima najširi spektar indikacija i zajedno ove dve pečurke čine dobru kombinaciju u lečenju problema pluća i jetre, i pružaju dobru opštu podršku.

Ključni sastojci: triterpeni i polisaharidi.

Doza: Čang kaže da je dnevna doza u opštenarodnoj upotrebi 25-300 g karpofora u formi esencije (vodenog ekstrakta), i da su slučajevi spontane remisije postignuti korišćenjem sličnih doza. Razmere zasićenosti ekstrakta najčešće variraju 12-18:1. Ukoliko je prosečna razmera zasićenosti 15:1, to je 2-20g ekstrakta dnevno, a pritom većina ljudi koristi niži stepen spektra, tj. 3-6 g dnevno. Za ostale probleme uobičajene su niže doze 1-3 g dnevno.

Nivoi polisaharida i triterpena najviši su u karpoforu i tradicionalno se ekstrahuju dobijanjem esencije u vreloj vodi (tj. prokuvavanjem i pravljenjem čaja). Ipak, iako je vodeni ekstrakt idealan za polisaharide, koji su visokorastvorljivi u vodi, triterpeni se slabo rastvaraju u vodi, ali se lako rastvaraju u alkoholu. Pošto se polisaharidi istalože iz rastvora alkohola, neki proizvođači dopunjuju vodeni ekstrakt bogat polisaharidima s triterpenima dobijenim iz alkoholnih rastvora i tako kombinuju pozitivne strane polisaharida i triterpena dobijenih iz G. lucidum.

Oprez - Potreban kod pacijenata koji horiste lekove protiv hipertenzije ili sedative. Antikoagulantna svojstva G. lucidum znače da je oprez potreban i kada se koristi s drugim antikoagulantima (lekovima).

Ovaj tekst i sajt su edukativnog karaktera, namenjeni za opšte obrazovanje i u informativne svrhe, nisu zamena za profesionalni medicinski savet, ispitivanje, dijagnozu ili lečenje.

REFERENCE:

1. Akihisa T, Nakamura Y, Tagata M, editors. et al. Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum. Chem Biodivers. 2007;4:224–31. [PubMed]

2. Bao X, Liu C, Fang J, Li X. Structural and immunological studies of a major polysaccharide from spores of Ganoderma lucidum (Fr.) Karst. Carbohydr Res. 2001;332:67–74. [PubMed]

3. Bao X, Wang X, Dong Q, Fang J, Li X. Structural features of immunologically active polysaccharides from Ganoderma lucidum. Phytochemistry. 2002;59:175–81. [PubMed]

4. Benzie I. F. F, Wachtel-Galor S. Biomarkers of long-term vegetarian diets. Adv Clin Chem. 2009;47:169–220.

5. Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 2007;13:265–301. [PubMed]

6. Borchers A. T, Krishnamurthy A, Keen C. L, Meyers F. J, Gershwin M. E. The immunobiology of mushrooms. Exp Biol Med. 2008;233:259–76. [PubMed]

7. Borchers A. T, Stern J. S, Hackman R. M, Keen C. L, Gershwin M. E. Minireview: Mushrooms, tumors and immunity. Proc Soc Exp Biol Med. 1999;221:281–93. [PubMed]

8. Budavari S. The Merck Index. elevan. New Jersey: Merck & Co., INC; 1989. p. 845.

9. Cao L. Z, Lin Z. B. Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett. 2002;83:163–9. [PubMed]

10. Cao Q. Z, Lin Z. B. Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide. Acta Pharmacol Sin. 2004;25:833–8. [PubMed]

11. Cao Q. Z, Lin Z. B. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci. 2006;78:1457–63. [PubMed]

12. Cao Q. Z, Lin S. Q, Wang S. Z. Effect of Ganoderma lucidum polysaccharides peptide on invasion of human lung carcinoma cells in vitro. Beijing Da Xue Xue Bao. 2007;39:653–6. [PubMed]

13. Chang S. T, Buswell J. A. Mushroom nutriceuticals. World J Microbiol Biotechnol. 1996;12:473–6.

14. Chang S. T, Buswell J. A. Ganoderma lucidum (Curt.: Fr.) P. Karst. (Aphyllophoromycetideae): A mushrooming medicinal mushroom. Int J Med Mushrooms. 1999;1:139–46.

15. Chang S. T, Buswell J. A. Safety, quality control and regulational aspects relating to mushroom nutriceuticals. Proc. 6th Intl. Conf. Mushroom Biology and Mushroom Products. 2008:188–95. GAMU Gmbh, Krefeld, Germany.

16. Chang Y. H, Yang J. S, Yang J. L, editors. et al. Ganoderma lucidum extract promotes immune responses in normal BALB/c mice in vivo. Vivo. 2009;23:755–9. [PubMed]

17. Chen Y, Bicker W, Wu J, Xie M. Y, Lindner W. Ganoderma species discrimination by dual-mode chromatographic fingerprinting: A study on stationary phase effects in hydrophilic interaction chromatography and reduction of sample misclassification rate by additional use of reversed-phase chromatography. J Chromatogr. 2010;1217(8):1255–65. [PubMed]

18. Chen T. Q, Li K. B, He X. J, Zhu P. G, Xu J. Micro-morphology, chemical components and identification of log-cultivated Ganoderma lucidum spore. Lu M, Gao K, Si H. -F, Chen M. -J. Proc '98 Nanjing Intl Symp Science & Cultivation of Mushrooms. 1998 214. Nanjing, China. JSTC-ISMS.

19. Chen D. H, Shiou W. Y, Wang K. C, editors. et al. Chemotaxonomy of triterpenoid pattern of HPLC of Ganoderma lucidum and Ganoderma tsugae. J Chin Chem Soc. 1999;46:47–51.

20. Chen H. S, Tsai Y. F, Lin S, editors. et al. Studies on the immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg Med Chem. 2004;12:5595–601. [PubMed]

21. Chen Y, Zhu S. B, Xie M. Y, editors. et al. Quality control and original discrimination of Ganoderma lucidum based on high-performance liquid chromatographic fingerprints and combined chemometrics methods. Anal Chim Acta. 2008;623:146–56. [PubMed]

22. Chien C. M, Cheng J. L, Chang W. T, editors. et al. Polysaccharides of Ganoderma lucidum alter cell immunophenotypic expression and enhance CD56+ NK-cell cytotoxicity in cord blood. Bioorg Med Chem. 2004;12:5603–9. [PubMed]

23. Chiu S. W, Wang Z. M, Leung T. M, Moore D. Nutritional value of Ganoderma extract and assessmentof its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chem Toxicol. 2000;38:173–8. [PubMed]

24. Chung W. T, Lee S. H, Kim J. D. et al. Effect of mycelial culture broth of Ganoderma lucidum on the growth characteristics of human cell lines. J Biosci Bioeng. 2001;92:550–5. [PubMed]

25. Collins A. R. Antioxidant intervention as a route to cancer prevention. Eur J Cancer. 2005;41:1923–30. [PubMed]

26. Donk M. A. A conspectus of the families of Aphyllophorales. Persoonia. 1964;3:19–24.

27. Du M, Wang C, Hu X. C, Zhao G. Positive effect of selenium on the immune regulation activity of lingzhi or reishi medicinal mushroom, Ganoderma lucidum (W. Curt.: Fr.) P. Karst. (Aphyllophoromycetideae), proteins in vitro. Int J Med Mushrooms. 2008;10:337–44.

28. El-Mekkawy S, Meselhy M. R, Nakamura N, editors. et al. Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum. Phytochemistry. 1998;49:1651–7. [PubMed]

29. Eo S. K, Kim Y. S, Lee C. K, Han S. S. Antiviral activities of various water and methanol soluble substances isolated from Ganoderma lucidum. J Ethnopharmacol. 1999;68:129–36. [PubMed]

30. Evans S, Dizeyi N, Abrahamsson P. A, Persson J. The effect of novel botanical agent TBS-101 on invasive prostate cancer in animal models. Anticancer Res. 2009;29:3917–24. [PubMed]

31. Falandysz J. Selenium in edible mushrooms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2008;26(3):256–99. [PubMed]

32. Fang Q. H, Zhong J. J. Two-stage culture process for improved production of ganoderic acid by liquid fermentation of higher fungus Ganoderma lucidum. Biotechnol Prog. 2002;18:51–4. [PubMed]

33. Fukuzawa M, Yamaguchi R, Hide I, editors. et al. Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol Pharm Bull. 2008;31:1933–7. [PubMed]

34. Furusawa E, Chou S. C, Furusawa S, Hirazumi A, Dang Y. Antitumour activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted Lewis lung carcinoma in synergenic mice. Phytother Res. 1992;6:300–4.

35. Gao Y, Gao H, Chan E, editors. et al. Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunol Invest. 2005;34:171–98. [PubMed]

36. Gao Y, Lan J, Dai X, Ye J, Zhou S. A phase I/II study of Lingzhi mushroom Ganoderma lucidum (W. Curt.: Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with type II diabetes mellitus. Int J Med Mushrooms. 2004;6:33–40.

37. Gao J. J, Min B. S, Ahn E. M, Nakamura N, Lee H. K, Hattori M. New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem Pharm Bull. 2002;50:837–40. [PubMed]

38. Gao Y. H, Sai X. H, Chen G. L, Ye J. X, Zhou S. F. A randomized, placebo-controlled, multi-center study of Ganoderma lucidum (W. Curt.: Fr.) Lloyd (Aphyllophoromycetideae) polysaccharides (Ganopoly) in patients with advanced lung cancer. Int J Med Mushrooms. 2003;5:368–81.

39. Gao Y, Tang W, Gao H, Chan E, Lan J, Zhou S. Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats. J Med Food. 2004;7(4):417–21. [PubMed]

40. Gao Y, Zhou S. Cancer prevention and treatment by Ganoderma, a mushroom with medicinal properties. Food Rev Int. 2009;19:275–325.

41. Gao Y. H, Zhou S. F, Chen G. L, Dai X. H, Ye J. X. A phase I/II study of a Ganoderma lucidum (Curr.: Fr.) P. Karst. Extract (Ganopoly) in patients with advanced cancer. Int J Med Mushrooms. 2002;4:207–14.

42. Gao Y. H, Zhou S. F, Jiang W. Q, Huang M, Sai X. H. Effects of Ganopoly (a Ganoderma lucidum polysaccharide extract) on immune functions in advanced-stage cancer patients. Immunol Invest. 2003;32:201–15. [PubMed]

43. Gonzalez A. G, Leon F, Rivera A, Munoz C. M, Bermejo J. Lanostanoid triterpenes from Ganoderma lucidum. J Nat Prod. 1999;62:1700–1.

44. Gottlieb A. M, Ferref E, Wright J. E. rDNA analyses as an aid to the taxonomy of species of Ganoderma. Mycol Res. 2000;104:1033–45.

45. Gottlieb A. M, Saidman B. O, Wright J. E. Isoenzymes of Ganoderma species from southern South America. Mycol Res. 1998;102:415–26.

46. Habijanic J, Berovic M. The relevance of solid-state substrate moisturing on Ganoderma lucidum biomass cultivation. Food Technol Biotechnol. 2000;38:225–8.

47. Haralampidis K, Trojanowska M, Osbourn A. E. Biosynthesis of triterpenoid saponins in plants. Adv Biochem Eng Biotechnol. 2002;75:31–49. [PubMed]

48. Hijikata Y, Yamada S. Effect of Ganoderma lucidum on postherpetic neuralgia. Am J Chin Med. 1998;26:375–81. [PubMed]

49. Hijikata Y, Yamada S, Yasuhara A. Herbal mixtures containing the mushroom Ganoderma lucidum improve recovery time in patients with herpes genitalis and labialis. J Altern Complement Med. 2007;13:985–7. [PubMed]

5O. Hikino H, Ishiyama M, Suzuki Y, Konno C. Mechanisms of hypoglycemic activity of ganoderan B: A glycan of Ganoderma lucidum fruit body. Planta Med. 1989;55:423–8. [PubMed]

51. Hikino H, Konno C, Mirin Y, Hayashi T. Isolation and hypoglycemic activity of ganoderans A and B, glycans of Ganoderma lucidum fruit bodies. Planata Med. 1985;4:339–40. [PubMed]

52. Ho Y. W, Yeung J. S, Chiu P. K, Tang W. M, Lin Z. B, Man R. Y, Lau C. S. Ganoderma lucidum polysaccharide peptide reduced the production of proinflammatory cytokines in activated rheumatoid synovial fibroblast. Mol Cell Biochem. 2007;301:173–9. [PubMed]

53. Hong K. J, Dunn D. M, Shen C. L, Pence B. C. Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother Res. 2004;18:768–70. [PubMed]

54. Hseu R. S, Wang H. H, Wang H. F, Moncalvo J. M. Differentiation and grouping of isolates of Ganoderma lucidum complex by random amplified polymorphic DNA-PCR compared with grouping on the basis of internal transcribed spacer sequences. Appl Environ Microbiol. 1996;62:1354–63. [PMC free article] [PubMed]

55. Hsiao W. L, Li Y. Q, Lee T. L, Li N, You M. M, Chang S. T. Medicinal mushroom extracts inhibit ras-induced cell transformation and the inhibitory effect requires the presence of normal cells. Carcinogenesis. 2004;25:1177–83. [PubMed]

56. Hu H, Ahn N. S, Yang X, Lee Y. S, Kang K. S. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 2002;102:250–3. [PubMed]

57. Hyun J. W, Choi E. C, Kim B. K. Studies on constituents of higher fungi of Korea (LXVII), antitumor components of the basidiocarp of Ganoderma lucidum. Korean J Mycol. 1990;18:58–69.

58. Ji Z, Tang Q, Zhang J, Yang Y, Jia W, Pan Y. Immunomodulation of RAW264.7 macrophages by GLIS, a proteopolysaccharide from Ganoderma lucidum. J Ethnopharmacol. 2007;112:445–50. [PubMed]

59. Jia J, Zhang X, Hu Y. S, editors. et al. Evaluation of in vivo antioxidant activities of Ganoderma lucidum poly- saccharides in STZ-diabetic rats. Food Chem. 2009;115:32–6.

60. Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med. 2008;21:577–84. [PubMed]

61. Jiang J, Slivova V, Sliva D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol. 2006;29:695–703. [PubMed]

62. Jiang J, Slivova V, Valachovicova T, Harvey K, Sliva D. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol. 2004;24:1093–9. [PubMed]

63. Johnston N. Medicinal mushroom cuts off prostate cancer cells’ blood supply. Drug Discov Today. 2005;10:1584. [PubMed]

64. Kawagishi H, Mitsunaga S. I, Yamawaki M, editors. et al. A lectin from mycelia of the fungus Ganoderma lucidum. Phytochemistry. 1997;44:7–10. [PubMed]

65. Keypour S, Riahi H, Moradali M. F, Rafati H. Investigation of the antibacterial activity of a chloroformextract of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (W. Curt.: Fr.) P. Karst. (Aphyllophoromycetideae). Int J Med Mushrooms. 2008;10(4):345–9.

66. Kim B. K, Chung H. S, Chung K. S, Yang M. S. Studies on the antineoplastic components of Korean basidiomycetes. Korean J Mycol. 1980;8:107–13.

67. Kim Y. S, Eo S. K, Oh K. W, Lee C. K, Han S. S. Antiherpetic activities of acidic protein bound polysaccharide isolated from Ganoderma lucidum alone and in combinations with interferons. J Ethnopharmacol. 2000;72:451–8. [PubMed]

66. Kim K. C, Kim J. S, Son J. K, Kim I. G. Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by the Ganoderma lucidum and Duchesnea chrysantha extracts. Cancer Lett. 2007;246:210–17. [PubMed]

69. Kim S. D, Nho H. J. Isolation and characterization of alpha-glucosidase inhibitor from the fungus Ganoderma lucidum. J Microbiol. 2004;42:223–7. [PubMed]

70. Kim H. M, Park M. K, Yun J. W. Culture pH affects exopolysaccharide production in submerged mycelial culture of Ganoderma lucidum. Appl Biochem Biotechnol. 2006;134:249–62. [PubMed]

71. Kim D. H, Shim S. B, Kim N. J, Jang I. S. β-Glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol Pharm Bull. 1999;22:162–4. [PubMed]

72. Kimura Y, Taniguchi M, Baba K. Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: Mechanism of action and isolation of an active substance. Anticancer Res. 2002;22:3309–18. [PubMed]

73. Kolesnikova O. P, Tuzova M. N, Kozlov V. A. Screening of immunoactive properties of alkanecarbonic acid derivatives and germanium-organic compounds in vivo. Immunologiya. 1997;10:36–8.

74. Kubota T, Asaka Y, Miura I, Mori H. Structures of ganoderic acids A and B, two new lanostane type bitter triterpenes from Ganoderma lucidum (Fr.) Karst. Helv Chim Acta. 1982;65:611–9.

75. Kuo M. C, Weng C. Y, Ha C. L, Wu M. J. Ganoderma lucidum mycelia enhance innate immunity by activating NF-kappaB. J Ethnopharmacol. 2006;103:217–22. [PubMed]

76. Lakshmi B, Ajith T. A, Jose N, Janardhanan K. K. Antimutagenic activity of methanolic extract of Ganoderma lucidum and its effect on hepatic damage caused by benzo[a]pyrene. J Ethnopharmacol. 2006;107(2):297–303. [PubMed]

77. Lee J. M, Kwon H, Jeong H, editors. et al. Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001;15:245–9. [PubMed]

78. Lee K. M, Lee S. Y, Lee H. Y. Bistage control of pH for improving exopolysaccharide production from mycelia of Ganoderma lucidum in an air-lift fermentor. J Biosci Bioeng. 1999;88:646–50. [PubMed]

79. Lee S. S, Wei Y. H, Chen C. F, Wang S. Y, Chen K. Y. Antitumor effects of Ganoderma lucidum. J Chin Med. 1995;6:1–12.

80. Li C. H, Chen P. Y, Chang U. M, editors. et al. Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. Life Sci. 2005;77:252–65. [PubMed]

81. Li Y. Q, Wang S. F. Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum. Biotechnol Lett. 2006;28(11):837–41. [PubMed]

82. Li Z, Liu J, Zhao Y. Possible mechanism underlying the antiherpetic activity of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Biochem Mol Biol. 2005;38(1):34–40. [PubMed]

83. Lin S. C. Beijing, China: Chinese Agricultural Press; Medicinal Fungi of China-Production and Products Development. 2000

84. Lin S. B, Li C. H, Lee S. S, Kan L. S. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing proteinkinase C, activating mitogen-activated protein kin/spanspan class=ases and G2-phase cell cycle arrest. Life Sci. 2003;72:2381–90. [PubMed]

85. Lin J. M, Lin C. C, Chen M. F, Ujiie T, Takada A. Radical scavenger and antihepatotoxic activity of Ganoderma formosanum, Ganodermalucidum and Ganoderma neo-japonicum. J Ethnopharmacol. 1995;47:33–41. [PubMed]

86. Lindequist U, Niedermeyer T. H, Jülich W. D. The pharmacological potential of mushrooms. Evid Based Complement Alternat Med. 2005;2:285–99. [PMC free article] [PubMed]

87. Liu K. C, Phounsavan S. F, Huang R. L, Liao C, Hsu S. Y, Wang K. J. Pharmacological and liver functional studies on mycelium of Ganoderma lucidum. Chin Pharm J. 1998;40:21–9.

88. Liu J, Shimizu K, Konishi F, editors. et al. Anti-androgenic activities of the triterpenoids fraction of Ganoderma lucidum. Food Chem. 2007a;100:1691–6.

89. Liu J, Shimizu K, Konishi F, Kumamoto S, Kondo R. The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum. Bioorg Med Chem. 2007b;15:4966–72. [PubMed]

90. Liu J, Yang F, Ye L. B, Yang X. J, Timani K. A, Zheng Y, Wang Y. H. Possible mode of action of antiherpetic activities of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Ethnopharmacol. 2004;95:265–72. [PubMed]

91. Liu Y. W, Gao J. L, Guan J, Qian Z. M, Feng K, Li S. P. Evaluation of antiproliferative activities and action mechanisms of extracts from two species of Ganoderma on tumor cell lines. J Agric Food Chem. 2009;57:3087–93. [PubMed]

92. Liu X, Yuan J. P, Chung C. K, Chen X. J. Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum. Cancer Lett. 2002;182:155–61. [PubMed]

93. Lu Q. Y, Jin Y. S, Zhang Q, editors. et al. Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Lett. 2004;216:9–20. [PubMed]

94. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. A water-soluble extract from cultured medium of Ganoderma lucidum (Reishi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep. 2003;10:375–9. [PubMed]

95. Lu H, Uesaka T, Katoh O, Kyo E. Watanabe H. Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats. Oncol Rep. 2001;8:1341–5. [PubMed]

96. Ma C, Guan S. H, Yang M, Liu X, Guo D. A. Differential protein expression in mouse splenic mononuclear cells treated with polysaccharides from spores of Ganoderma lucidum. Phytomedicine. 2008;15:268–76. [PubMed]

97. Ma J, Ye Q, Hua Y, editors. et al. New lanostanoids from the mushroom Ganoderma lucidum. J Nat Prod. 2002;65:72–5. [PubMed]

98. Mahato S. B, Sen S. Advances in triterpenoid research, 1990-1994. Phytochemistry. 1997;44:1185–236. [PubMed]

99. Mao T, Van de Water J, Keen C. L, Stem J. S, Hackman R, Gershwin M. E. Two mushrooms, Grifola frondosa and Ganoderma lucidum, can stimulate cytokine gene expression and proliferation in human T lymphocytes. Int J Immunother. 1999;15:13–22.

100. Mashour N. K, Lin G. I, Frishman W. H. Herbal medicine for the treatment of cardiovascular disease: Clinical considerations. Arch Intern Med. 1998;158:2225–34. [PubMed]

101. Mau J. L, Lin H. C, Chen C. C. Non-volatile components of several medicinal mushrooms. Food Res Int. 2001;34:521–6.

102. Mau J. L, Lin H. C, Chen C. C. Antioxidant properties of several medicinal mushrooms. J Agric Food Chem. 2002;50:6072–7. [PubMed]

103. Mayzumi F, Okamoto H, Mizuno T. Cultivation of Reishi. Food Rev Int. 1997;13:365–73.

104. McMeekin D. The perception of Ganoderma lucidum in Chinese and Western culture. Mycologist. 2005;18:165–9.

105. Min B. S, Gao J. J, Nakamura N, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells. Chem Pharm Bull. 2000;48:1026–33. [PubMed]

106. Min B. S, Nakamura N, Miyashiro H, Bae K. W, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Chem Pharm Bull. 1998;46:1607–12. [PubMed]

107. Mino Y, Ota N, Sakao S, Shi momura S. Determination of germanium in medicinal plants by atomic absorption spectrometry with electrothermal atomization. Chem Pharm Bull. 1980;28:2687–91. [PubMed]

108. Miura T, Yuan L, Sun B, editors. et al. Isoflavone aglycon produced by culture of soybean extracts with basidiomycetes and its anti-angiogenic activity. Biosci Biotechnol Biochem. 2002;66:2626–31. [PubMed]

109. Miyazaki T, Nishijima M. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chem Pharm Bull. 1981;29:3611–16. [PubMed]

110. Moncalvo J. M. Systematics of Ganoderma. In: Ganoderma Diseases of Perennial Crops. Wallingford, UK: CAB International; 2000. pp. 23–45.

111. Moncalvo J. M, Wang H. F, Wang H. H, Hseu R. S. The use of rDNA nucleotide sequence data for species identification and phylogeny in the Ganodermataceae. In: Ganoderma: Systematics. Phytopathology and Pharmacology. Taipei: Department of Agricultural Chemistry, National Taiwan University; 1995.

112. Muller C. I, Kumagai T, O'Kelly J, Seeram N. P, Heber D, Koeffler H. P. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res. 2006;30:841–8. [PubMed]

113. Nishitoba T, Sato H, Kasai T, Kawagishi H, Sakamura S. New bitter C27 and C30 terpenoids from fungus Ganoderma lucidum (Reishi). Agric Biol Chem. 1984;48:2905–7.

114. Nonaka Y, Shibata H, Nakai M, editors. et al. Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice. Biosci Biotechnol Biochem. 2006;70:2028–34. [PubMed]

115. Oh K. W, Lee C. K, Kim Y. S, Eo S. K, Han S. S. Antiherpetic activities of acidic protein bound polysacchride isolated from Ganoderma lucidum alone and incombination with Acyclovir and Vidarabine. J Ethnopharmacol. 2000;72:221–7. [PubMed]

116. Ohno N, Miura N. N, Sugawara N, Tokunaka K, Kirigaya N, Yadomae T. Immunomodulation by hot water and ethanol extracts of Ganoderma lucidum. Pharm Pharmacol Lett. 1998;4:174–7.

117. Ooi V. E, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000;7:715–29. [PubMed]

118. Park E. J, Ko G, Kim J, Dong H. S. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, Glycyrrhizin, and Pentoxifylline in rats with cirrhosis induced by biliary obstruction. Biol Pharm Bull. 1997;20:417–20. [PubMed]

119. Paterson R. R. Ganoderma-a therapeutic fungal biofactory. Phytochemistry. 2006;67(18):1985–2001. [PubMed]

120. Riu H, Roig G, Sancho J. Production of carpophores of Lentinus edodes and Ganoderma lucidum grown on cork residues. Microbiologia SEM. 1997;13:185–92. [PubMed]

121. Ryvarden L. Can we trust morphology in Ganoderma? Buchanan P. K, Hseu R. S, Moncalvo J. M. Ganoderma: Systematics, Phytopathology and Pharmacology. Proceedings of Contributed Symposium. 1994:19–24. 59A, B 5th International Mycological Congress August 14-21 1994.

122. Sadava D, Still D. W, Mudry R. R, Kane S. E. Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett. 2009;277:182–9. [PubMed]

123. Saltarelli R, Ceccaroli P, Iotti M, editors. et al. Biochemical characterisation and antioxidant activity of mycelium of Ganoderma lucidum from Central Italy. Food Chem. 2009;116:143–51.

124. Sanodiya B. S, Thakur G. S, Baghel R. K, Prasad G. B, Bisen P. S. Ganoderma lucidum: A potent pharmacological macrofungus. Curr Pharm Biotechnol. 2009;10(8):717–42. [PubMed]

125. Sato H, Nishitoba T, Shirasu S, Oda K, Sakamura S. Ganoderiol A and B, new triterpenoids from the fungus Ganoderma lucidum (Reishi). Agric Biol Chem. 1986;50:2887–90.

126. Seto S. W, Lam T. Y, Tam H. L, editors. et al. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine. 2009;16(5):426–36. [PubMed]

127. Shang D, Zhang J, Wen L, Li Y, Cui Q. Preparation, characterization, and antiproliferative activities of the Se-containing polysaccharide SeGLP-2B-1 from Se-enriched Ganoderma lucidum. J Agric Food Chem. 2009;57:7737–42. [PubMed]

128. Sheena M, Ajith A, Janardhanan K. Prevention of nephrotoxicity induced by the anticancer drug Cisplatin, using Ganoderma lucidum, a medicinal mushroom occuring in South India. Curr Sci. 2003;85:478–82.

129. Shi Y. L, James A. E, Benzie I. F, Buswell J. A. Mushroom-derived preparations in the prevention of H2O2-induced oxidative damage to cellular DNA. Teratog Carcinog Mutagen. 2002;22:103–11. [PubMed]

130. hi Y, Sun J, He H, Guo H, Zhang S. Hepatoprotective effects of Ganoderma lucidum peptides against D-galactosamine-induced liver injury in mice. J Ethnopharmacol. 2008;117:415–19. [PubMed]

131. Shi X. M, Zhang J. S, Tang Q. J, Yang Y, Hao R. X, Pan Y. J. Fingerprint analysisof lingzhi (Ganoderma) strains by high-performance liquid chromatography coupled with chemometric methods. World J Microbiol Biotechnol. 2008;24:2443–50.

132. Shieh Y. H, Liu C. F, Huang Y. K, Yang J. Y, Wu I. L, Lin C. H, Lin S. C. Evaluation of the hepatic and renal protective effects of Ganoderma lucidum in mice. Am J Chin Med. 2001;29:501–7. [PubMed]

133. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem. 2004;4:873–9. [PubMed]

134. Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd F. P Jr, Ho N. W. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun. 2002;298:603–12. [PubMed]

135. Song Y. S, Kim S. H, Sa J. H, Jin C, Lim C. J, Park E. H. Anti-angiogenic and inhibitory activity on inducible nitric oxide production of the mushroom Ganoderma lucidum. J Ethnopharmacol. 2004;90:17–20. [PubMed]

136. Song C. H, Yang B. K, Ra K. S, Shon D. H, Park E. J, Go G. I, Kim Y. H. Hepatoprotective effect of extracellular polymer produced by submerged culture of Ganoderma lucidum WK-003. J Microbiol Biotechnol. 1998;8:277–9.

137. Stanley G, Harvey K, Slivova V, Jiang J, Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem Biophys Res Commun. 2005;330:46–52. [PubMed]

138. Su C. H, Yang Y. Z, Ho H, Hu C. H, Sheu M. T. High-performance liquid chromatographic analysis for the characterization of triterpenoids from Ganoderma. J Chromatogr Sci. 2001;39:93–100. [PubMed]

139. Sun S. J, Gao W, Lin S. Q, Zhu J, Xie B. G, Lin Z. B. Analysis of genetic diversity in Ganoderma populations with a novel molecular marker SRAP. Appl Microbiol Biotechnol. 2006;72:537–43. [PubMed]

140. Sun J, He H, Xie B. J. Novel antioxidant peptides from fermented mushroom Ganoderma lucidum. J Agric Food Chem. 2004;52:6646–52. [PubMed]

141. Tang W, Liu J. W, Zhao W. M, Wei D. Z, Zhong J. J. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci. 2006;80:205–11. [PubMed]

142. Thakur A, Rana M, Lakhanpal T. N, Ahmad A, Khan M. I. Purification and characterization of lectin from fruiting body of Ganoderma lucidum: Lectin from Ganoderma lucidum. Biochim Biophys Acta. 2007;1770:1404–12. [PubMed]

143. The State Pharmacopoeia Commission of P. R. China. State Pharmacopoeia Commission of the People’s Republic of China. Beijing, China: Chemical Industry Press; 2000.

144. Tomasi S, Lohezic-Le D. F, Sauleau P, Bezivin C, Boustie J. Cytotoxic activity of methanol extracts from Basidiomycete mushrooms on murine cancer cell lines. Pharmazie. 2004;59:290–3. [PubMed]

145. Tomoda M, Gonda R, Kasahara Y, Hikino H. Glycan structures of ganoderans B and C, hypoglycemic glycans of Ganoderma lucidum fruit bodies. Phytochemistry. 1986;25:2817–20.

146. Upton R. American Herbal Pharmacopeia and Therapeutic Compendium: Reishi Mushroom, Ganoderma lucidum. Standards of Analysis, Quality Control, and Therapeutics. U.S.A. Canada: Santa Cruz; 2000.

147. Van Der Hem L, Van Der Vliet A, Bocken C. F. M, Kino K, Hoitsma A. J, Tax W. J. M. Lingzhi-8: Studies of a new immunomodulating agent. Transplantation. 1995;60:438–43. [PubMed]

148. Wachtel-Galor S, Buswell J. A, Tomlinson B, Benzie I. F. F. Lingzhi polyphorous fungus. In: Herbal and Traditional Medicine: Molecular Aspects of Health. New York: Marcel Dekker Inc; 2004. pp. 179–228.

149. Wachtel-Galor S, Choi S. W, Benzie I. F. F. Effect of Ganoderma lucidum on human DNA is dose dependent and mediated by hydrogen peroxide. Redox Rep. 2005;10(3):145–9. [PubMed]

150. Wachtel-Galor S, Szeto Y. T, Tomlinson B, Benzie. F I. F. Ganoderma lucidum (Lingzhi): Acute and short-term biomarker response to supplementation. Int J Food Sci Nutr. 2004;1:75–83. [PubMed]

151. Wang S. Y, Hsu M. L, Hsu H. C, editors. et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 1997;70:699–705. [PubMed]

152. Wang Y. Y, Khoo K. H, Chen S. T, Lin C. C, Wong C. H, Lin C. H. Studies on the immunomodulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: Functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem. 2002;10:1057–62. [PubMed]

153. Wang H, Ng T. B. Ganodermin, an antifungal protein from fruiting bodies of the medicinal mushroom Ganoderma lucidum. Peptides. 2006;27:27–30. [PubMed]

154. Wang H, Ng T. B, Ooi V. E. C. Lectins from mushrooms. Mycol Res. 1998;102:897–906.

155. Wang G, Zhao J, Liu J, Huang Y, Zhong J. J, Tang W. Enhancement of IL-2 and IFN-gamma expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me in vivo. Int Immunopharmacol. 2007;7:864–70. [PubMed]

156. Wasser S. P, Coates P, Blackman M, Cragg G, Levine M, Moss J, White J. Encyclopedia of Dietary Supplements. New York: Marcel Dekker; 2005. Reishi or Lingzhi (Ganoderma lucidum); pp. 680–90.

157. Wasser S. P, Weis A. L. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: Current perspectives. Int J Med Mushrooms. 1999;1:31–62.

158. Wen H, Kang S, Song Y, Song Y, Sung S. H, Park S. Differentiation of cultivation sources of Ganoderma lucidum by a NMR-based metabolomics approach. Phytochem Anal. 2010;21:73–9. [PubMed]

159. Weng C. J, Chau C. F, Yen G. C, Liao J. W, Chen D. H, Chen K. D. Inhibitory effects of Ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models. J Agric Food Chem. 2009;57:5049–57. [PubMed]

160. WHO (World Health Organization). Mortality Statistics. 2008. World Health Report.

161. Woo Y. A, Kim H. J, Cho J. H, Chung H. Discrimination of herbal medicines according to geographical origin with near infrared reflectance spectroscopy and pattern recognition techniques. J Pharm BiomedAnal. 1999;21:407–13. [PubMed]

162. Wu Y. W, Fang H. L, Lin W. C. Post-treatment of Ganoderma lucidum reduced liver fibrosis induced by thioacetamide in mice. PhytotherRes. 2010;24(4):494–9. [PubMed]

163. Wu Y, Wang D. A new class of natural glycopeptides with sugar moiety-dependent antioxidant activities derived from Ganoderma lucidum fruiting bodies. J Proteome Res. 2009;8:436–42. [PMC free article] [PubMed]

164. Wu Q. P, Xie Y. Z, Li S. Z, editors. et al. Tumour cell adhesion and integrin expression affected by Ganoderma lucidum. Enzyme Microb Technol. 2006;40:32–41.

165. Xie Y. Z, Li S. Z, Yee A, editors. et al. Ganoderma lucidum inhibits tumour cell proliferation and induces tumour cell death. Enzyme Microb Technol. 2009;40:177–85.

166. Xie J. T, Wang C. Z, Wicks S, editors. et al. Ganoderma lucidum extracts inhibits proliferation of SW 480 human colorectal cancer cells. Exp Oncol. 2006;28:25–9. [PubMed]

167. Yang F. C, Liau C. B. The influence of environmental conditions on polysaccharide formation by Ganoderma lucidum in submerged cultures. Process Biochem. 1998;33:547–53.

168. Yoon S. Y, Eo S. K, Kim Y. S, Lee C. K, Han S. S. Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics. Arch Pharm Res. 1994;17:438–42. [PubMed]

169. Yue Q. X, Xie F. B, Guan S. H, editors. et al. Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes. Cancer Sci. 2008;99:1461–70. [PubMed]

170. Yuen J. W, Gohel M. D. Anticancer effects of Ganoderma lucidum: A review of scientific evidence. Nutr Cancer. 2005;53:11–7. [PubMed]

171. Yuen J. W, Gohel M. D. The dual roles of Ganoderma antioxidants on urothelial cell DNA under carcinogenic attack. J Ethnopharmacol. 2008;118:324–30. [PubMed]

172. Yuen J. W, Gohel M. D, Au D. W. Telomerase-associated apoptotic events by mushroom Ganoderma lucidum on premalignant human urothelial cells. Nutr Cancer. 2008;60:109–9. [PubMed]

173. Yun T. K. Update from Asia: Asian studies on cancer chemoprevention. Ann N Y Acad Sci. 1999;889:157–92. [PubMed]

174. Zaidman B. Z, Yassin M, Mahajna J, Wasser S. P. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol. 2005;67:453–68. [PubMed]

175. Zhang Q. H, Lin Z. B. Antitumor activity of Ganoderma lucidum (Curt.: Tr.) P.Karst. (Lingzhi) (Aphyllophoromycetideae) polysaccharides is related to tumor necrosis factor-alpha and interferongamma. Int J Med Mushrooms. 1999;1:207–15.

176. Zhang W, Tang Y. J. A novel three-stage light irradiation strategy in the submerged fermentation of medicinal mushroom Ganoderma lucidum for the efficient production of ganoderic acid and Ganoderma polysaccharides. Biotechnol Prog. 2008;24:1249–61. [PubMed]

177. Zhang L, Zhang M, Chen J. Solution properties of antitumor carboxymethylated derivatives of a-(1→3)-D-Glucan from Ganoderma lucidum. Chin J Polym Sci. 2001;19:283–9.

178. Zhao L, Dong Y, Chen G, Hu H. Extraction, purification, characterization and antitumor activity of polysaccharides from Ganoderma lucidum. Carbohydr Polym. 2010;80(3):783–9.

179. Zhao J. D, Zhang X. Q. Importance, distribution and taxonomy of Ganodermataceae in China. Proceedings of Contributed Symposium, B 5th International Mycological Congress, Vancouver. 1994 1994 August 14-21;

180. Zheng L, Jia D, Fei X, Luo X, Yang Z. An assessment of the genetic diversity within Ganoderma strains with AFLP and ITS PCR-RFLP. Microbiol Res. 2009;164:312–21. [PubMed]

181. Zhong J. J, Xiao J. H. Secondary metabolites from higher fungi: Discovery, bioactivity and biopro-duction. Adv Biochem Eng Biotechnol. 2009;113:79–150. [PubMed]

182. Zhou X, Lin J, Yin Y, Zhao J, Sun X, Tang K. Ganodermataceae: Natural products and their related pharmacological functions. Am J Chin Med. 2007;35:559–74. [PubMed]

183. Zhu Y. P. Chinese Materia Medica. Singapore: Harwood Academic Publishers; 1998.

184. Zhu X. L, Chen A. F, Lin Z. B. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol. 2007;111:219–26. [PubMed]

185. Zhu X, Lin Z. Modulation of cytokines production, granzyme B and perforin in murine CIK cells by Ganoderma lucidum polysaccharides. Carbohydr Polym. 2006;63:188–97.

Obaveštenje

Ovaj sajt je namenjen za opšte obrazovanje i u informativne svrhe, nije zamena za profesionalni medicinski savet, ispitivanje, dijagnozu ili lečenje. Informacije preko ovog sajta ne smeju se koristiti za dijagnozu ili lečenje zdravstvenog problema ili bolesti. Sajt nije zamena za profesionalnu zdravstvenu zaštitu, dizajniran je u cilju da podrži, a ne da zameni odnos pacijent-lekar. Bez obzira na to kako se proizvodi mogu koristiti u drugim zemljama ili bilo šta što ste možda čuli ili pročitali o Aloha Medicinals proizvodima, po FDA zakonu u Sjedinjenim Američkim Državama, zakonom je zabranjeno proizvodjaču da tvrdi da je preparat lek. Nijedan od proizvoda navedenih na ovom sajtu nije namenjen da se koristi u lečenju svih bolesti. Sve izjave Aloha Medicinals su namenjene u informativne svrhe. Izjave nisu ocenjene od strane FDA,a proizvodi nisu namenjeni za dijagnozu, tretman, lečenje ili sprečavanje bilo koje bolesti. Zdravstvene odluke su isuviše važne da bi se donosile bez saveta lekara. Kao i kod svakog dodatka ishrani ili biljnog dodatka pre upotrebe konsultujte svog lekara o upotrebi proizvoda. Ako ste dojilja ili trudnica, pre upotrebe bilo kog preparata konsultujte svog lekara.

Zakon o autorskom pravu

Zakonom o autorskom pravu, razumete i saglasni ste da vam je isključivo dozvoljeno da koristite Sadržaj odobren ovim Ugovorom i da ne možete kopirati, umnožavati, distribuirati ili kreirati izvedene radove iz ovog Sadržaja bez prethodnog izričitog pismenog ovlašćenja vlasnika sajta. Uslovi korišćenja

Copyright ©2006-2017 www.moj-imunitet.com je namenjen isključivo ličnom, a ne komercijalnom korišćenju. | Sva prava zadržana.